A risk-adapted approach to acute GVHD treatment: are we there yet?
about
Plasma biomarkers of risk for death in a multicenter phase 3 trial with uniform transplant characteristics post-allogeneic HCT.Upper GI GVHD: similar outcomes to other grade II graft-versus-host disease.Predictive Value of Clinical Findings and Plasma Biomarkers after Fourteen Days of Prednisone Treatment for Acute Graft-versus-host Disease.Quality of life of patients with graft-versus-host disease (GvHD) post-hematopoietic stem cell transplantation.Inhibition of 5-lipoxygenase alleviates graft-versus-host disease.Hematopoietic stem cell transplantation in children with Griscelli syndrome: A single-center experience.Amphiregulin modifies the Minnesota Acute Graft-versus-Host Disease Risk Score: results from BMT CTN 0302/0802
P2860
Q37585022-E2EEAAE3-3615-483D-98CC-8D2795269D55Q38786092-52B7E881-FD35-4D4F-8869-9ED42F486124Q38800455-DEF29965-3358-4A35-AEE9-B32450A8D938Q47575184-B6B92B96-B894-442B-94EE-2352C0F6FAD9Q47744316-884E5F0A-4708-4BD4-948A-EB1FAF6B5B16Q48183641-79A4C100-F0DB-4F80-B687-8B3DCB1A1A66Q58797078-8C609010-B9AB-444F-9CCF-581681CDBF1B
P2860
A risk-adapted approach to acute GVHD treatment: are we there yet?
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
A risk-adapted approach to acute GVHD treatment: are we there yet?
@en
type
label
A risk-adapted approach to acute GVHD treatment: are we there yet?
@en
prefLabel
A risk-adapted approach to acute GVHD treatment: are we there yet?
@en
P2860
P356
P1476
A risk-adapted approach to acute GVHD treatment: are we there yet?
@en
P2093
M L MacMillan
S G Holtan
P2860
P2888
P304
P356
10.1038/BMT.2015.261
P407
P577
2015-11-09T00:00:00Z
P6179
1009949148